GÖTTINGEN, Germany, Jan. 6,
2021 /PRNewswire/ -- The life science company Sartorius
today announced it has entered into an agreement through its
subgroup Sartorius Stedim Biotech to acquire the chromatography
process equipment division of Novasep. The parties agreed not to
disclose the purchase price until the necessary regulatory
approvals have been obtained. Novasep's division expects to
generate sales revenue of approximately 37 million euros in
2020 at double-digit profit margins and employs approximately 100
people, the majority of whom work at its Pompey site in northern
France and some in the
USA, China and India. The proposed transaction is subject to
antitrust approvals and the information and consultation of
Novasep's works council and is expected to close during the first
half of 2021.
Novasep's chromatography unit comprises resin-based batch and
intensified chromatography systems, and primarily focuses on
high-pressure, multi-use applications for smaller molecules, such
as oligonucleotides, peptides and insulin. Since 2018, Novasep and
Sartorius have been collaborating in the joint development of an
optimized system for a membrane-based, low-pressure chromatography
that processes larger molecules more productively and that will be
launched soon.
"I am pleased that we will intensify our successful
collaboration with the Novasep team, soon to be under the Sartorius
roof," said Dr. René Fáber, Head of the Sartorius Bioprocess
Solutions Division and Executive Board member. "The Novasep
portfolio will perfectly complement our existing chromatography
offering and allow us to provide customers with more options for
their manufacturing processes. Efficient DSP has remained a
challenge in our industry for years, and Sartorius is committed to
helping accelerate and simplify this crucial step so that new drugs
can be manufactured much more efficiently. "
"This deal marks one of the first
steps in our Rise-2 strategic program to focus the group towards
our core business" said Dr. Michel
Spagnol, President & CEO of Novasep. "We are delighted
to strengthen our relationship with the Sartorius team and believe
it will be a great opportunity for the chromatography equipment
business to fully deliver its potential and accelerate its growth
under this new ownership. "
This press release contains forward-looking statements about the
future development of the Sartorius Group. Forward-looking
statements are subject to known and unknown risks, uncertainties
and other factors that could cause actual results to differ
materially from those expressed or implied by such statements.
Sartorius assumes no liability for updating such statements in
light of new information or future events. This is a translation of
the original German-language press release. Sartorius shall not
assume any liability for the correctness of this translation. The
original German press release is the legally binding version.
About Sartorius
The Sartorius Group is a leading international partner of life
science research and the biopharmaceutical industry. With
innovative laboratory instruments and consumables, the Group's Lab
Products & Services Division concentrates on serving the needs
of laboratories performing research and quality control at pharma
and biopharma companies and those of academic research institutes.
The Bioprocess Solutions Division with its broad product portfolio
focusing on single-use solutions helps customers to manufacture
biotech medications and vaccines safely and efficiently. The Group
has been annually growing by double digits on average and has been
regularly expanding its portfolio by acquisitions of complementary
technologies. In fiscal 2019, the company earned sales revenue of
some 1.83 billion euros. At the end
of 2019, more than 9,000 people were employed at the Group's
approximately 60 manufacturing and sales sites, serving customers
around the globe.
About Novasep
Novasep is a global provider of cost-effective and sustainable
manufacturing solutions for life sciences molecules and fine
chemicals. Novasep's unique offering includes process development
services, purification equipment and turnkey processes, contract
manufacturing services and complex active molecules to serve
pharmaceutical, biopharmaceutical, fine chemical, food and
functional ingredients, as well as fermentation and chemical
commodities industries. http://www.novasep.com
Sartorius contact
Petra Kirchhoff
Head of Corporate Communications and Investor Relations
+49 (0)551.308.1686
petra.kirchhoff@sartorius.com
www.sartorius.com
Novasep contacts
Brice Roquet / Laure
Saloin
Communication Project Managers
+33 7 77 94 37 55 / +33 7 77 94 37 52
brice.roquet@novasep.com / laure.saloin@novasep.com
Follow Sartorius on Twitter @Sartorius_Group and
on LinkedIn.
View original
content:http://www.prnewswire.com/news-releases/sartorius-to-acquire-novaseps-chromatography-process-equipment-division-301201842.html
SOURCE Sartorius AG